2021
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2015
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Research And Treatment 2015, 151: 697-707. PMID: 26022349, DOI: 10.1007/s10549-015-3432-1.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerDe novo metastatic breast cancerNovo metastatic breast cancerBreast cancer-specific survivalCancer-specific survivalHER2-positive tumorsOverall survivalBreast cancerTreatment patternsBlack patientsRacial differencesDisease subgroupsMultivariate Cox proportional modelEnd Results-Medicare dataHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Impact of raceHER2-positive diseaseHR-negative diseaseHR-negative tumorsLonger median OSMedian overall survivalGrowth factor receptor 2Survival of womenCox proportional models